Supplementary Material
Cholangiocarcinoma, Tumor
CHOLANGIOCARCINOMA, TUMOR
Supplementary MethodsClick here for additional data file.Supplementary Table 1. Dose-Limiting ToxicitiesClick here for additional data file.Supplementary Table 2. Representativeness of Study PatientsClick here for additional data file.Supplementary Table 3. Safety Summary by E7389-LF DoseClick here for additional data file.Supplementary Table 4. Pharmacokinetic Parameters After Administration of E7389-LFClick here for additional data file.Supplementary Table 5. Summary of Serum Nivolumab Concentrations After the First DoseClick here for additional data file.Supplementary Table 6. Analyses of Median Changes in Plasma Protein Expression of Biomarker Analytes From Baseline to C1D8 and C1D15 in All Dosing CohortsClick here for additional data file.Supplementary Table 7. Tumor Biomarkers: Assessment of Immune PhenotypesClick here for additional data file.S1. Box-and-Whisker Plot of Neutrophil Measurements During Cycle 1 for the (A) Q3W and (B) Q2W Dosing Groups.Click here for additional data file.S2. Linear (A) and Semi-logarithmic (B) Plasma Concentration Profiles of Eribulin After Administration of E7389-LF.Click here for additional data file.S3. Imaging of 2 Patients with Cholangiocarcinoma During Treatment.Click here for additional data file.S4. Gene Expression Profiling in Biopsy TissuesClick here for additional data file.